BPC-157: A Review of Preclinical Tissue Repair Research

Compound Overview

BPC-157 is a 15-amino-acid peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Also designated PL-10 in earlier literature, it was derived from the native body protection compound (BPC) isolated from human gastric juice. Its molecular weight is 1419.53 g/mol, and it is commercially synthesised as a stable analogue for laboratory research.

A defining characteristic of BPC-157 that distinguishes it from most research peptides is its exceptional stability profile. Unlike the majority of peptides, which degrade rapidly under acidic conditions, BPC-157 remains intact in gastric acid, saline, and human gastric juice for periods exceeding 24 hours. This stability is considered relevant to its origin — as a gastric-derived compound, it is structurally suited to resist the proteolytic and acidic environment of the stomach.

Proposed Mechanisms of Action

Multiple mechanistic pathways have been proposed and investigated across the BPC-157 preclinical literature. No single mechanism is considered definitive, and the compound's breadth of studied effects likely reflects involvement of several interconnected pathways.

• VEGFR2 upregulation and angiogenesis: BPC-157 has been shown in multiple models to upregulate vascular endothelial growth factor receptor 2 (VEGFR2), promoting angiogenesis — the formation of new blood vessels. This is considered a central mechanism in its studied effects on tissue healing, as vascularisation is a prerequisite for effective tissue repair.
• Nitric oxide (NO) system modulation: Both endothelial nitric oxide synthase (eNOS) and neuronal nitric oxide synthase (nNOS) pathways have been studied in the context of BPC-157 administration. Research suggests both stimulatory and modulatory effects on nitric oxide production depending on the tissue model and injury context.
• EGR-1 upregulation: Early growth response protein 1 (EGR-1) is a transcription factor that regulates genes involved in cell growth, differentiation, and tissue repair. Upregulation of EGR-1 has been proposed as a downstream mechanism linking BPC-157 administration to fibroblast activation and extracellular matrix remodelling.
• Growth hormone receptor (GHR) signalling: Interaction with the growth hormone receptor signalling axis has been proposed, potentially contributing to the anabolic and repair-associated effects observed in musculoskeletal models.

Tendon and Ligament Research

The tendon-to-bone healing model has been one of the most extensively investigated contexts for BPC-157. Chang CH et al. (2011) published a landmark study in the Journal of Orthopaedic Surgery and Research demonstrating accelerated tendon-to-bone healing in rat models following BPC-157 administration. Histological analysis showed improved collagen fibre organisation and earlier vascularisation at the healing interface. The VEGFR2 pathway was identified as a primary driver of these effects, with treated animals showing significantly upregulated VEGFR2 expression at the healing tendon insertion site.

Subsequent studies by the Sikirić research group at Zagreb University extended these findings to medial collateral ligament transection models, Achilles tendon transection models, and quadriceps tendon injuries, consistently demonstrating improved biomechanical outcomes — including tensile strength and stiffness — in BPC-157-treated animals compared to controls.

Muscle Repair Research

Skeletal muscle crush injury models in rats have been used to evaluate BPC-157's effects on myofibril regeneration. Studies from the Sikirić laboratory and collaborating institutions have reported faster fibre regeneration, reduced necrotic tissue area, and improved functional recovery in treated animals. The proposed mechanism involves a combination of VEGFR2-driven vascularisation of the injured muscle bed and modulation of the inflammatory cascade during the early repair phase.

These models typically use gastrocnemius or quadriceps crush injury paradigms with morphometric analysis at 7, 14, and 28 days post-injury as primary endpoints.

Gastrointestinal Research

BPC-157 was originally characterised in the context of gastrointestinal physiology, and the GI tract remains one of the most studied tissue contexts. Research has investigated its effects in models of gastric ulcer prevention and healing, intestinal anastomosis healing (relevant to post-surgical recovery in animal models), inflammatory bowel disease models including colitis induced by cysteamine and acetic acid, and intestinal fistula closure. The compound's stability in gastric juice is considered directly relevant to these models, suggesting that orally administered BPC-157 may reach intestinal mucosa intact in sufficient concentrations for local activity — though this route of administration involves additional complexity in rodent models.

Bone and Periodontal Research

Preclinical studies have extended the BPC-157 tissue repair literature to bone healing models. Calvarial (skull) defect models in rats have been used to assess osteogenic potential, with histomorphometric analysis showing improved bone fill in BPC-157-treated defects compared to controls. Mandibular fracture models have similarly demonstrated accelerated mineralisation and improved biomechanical outcomes. Periodontal research has examined effects on alveolar bone regeneration and soft tissue attachment in periodontitis models.

Systemic and Organ Protection Effects

Beyond musculoskeletal and GI applications, BPC-157 has been studied in models of organ injury, including liver damage (induced by hepatotoxins such as ethanol and CCl4), cardiac ischaemia-reperfusion injury, and brain injury models. These systemic effects are proposed to relate to the compound's modulation of the nitric oxide system, given the central role of NO in vascular homeostasis and organ perfusion. It is important to note that these represent early-stage preclinical investigations and do not constitute evidence of clinical efficacy.

Dosing in Preclinical Models

The majority of published BPC-157 rodent studies have used doses in the range of 2–10 µg/kg administered intraperitoneally (i.p.) or subcutaneously (s.c.), typically once daily. Some studies have used lower doses of 0.01 µg/kg to demonstrate efficacy at nanogram-per-kilogram ranges, which has been cited as evidence of potent biological activity. Route of administration, dosing frequency, and the specific injury model all significantly influence observed outcomes.

The Sikirić Research Group

The preponderance of BPC-157 preclinical literature has been produced by the research group led by Professor Predrag Sikirić at the Zagreb University School of Medicine in Croatia. This group has published the majority of peer-reviewed studies on the compound across multiple tissue and organ systems, establishing the foundational body of evidence that subsequent researchers have built upon. Independent replication studies, while less numerous, have produced broadly consistent findings in tendon and angiogenesis models.